留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

蛋白激酶CK2α在大鼠肝纤维化病理过程中的表达变化

王珂琪,  许维恒,  丁力,  张俊平

downloadPDF
文章导航 > 药学实践与服务  > 2015 >  33(6): 518-521,575
王珂琪, 许维恒, 丁力, 张俊平. 蛋白激酶CK2α在大鼠肝纤维化病理过程中的表达变化[J]. 药学实践与服务, 2015, 33(6): 518-521,575. doi: 10.3969/j.issn.1006-0111.2015.06.010
引用本文: 王珂琪, 许维恒, 丁力, 张俊平. 蛋白激酶CK2α在大鼠肝纤维化病理过程中的表达变化[J]. 药学实践与服务, 2015, 33(6): 518-521,575. doi: 10.3969/j.issn.1006-0111.2015.06.010
shu
WANG Keqi, Xu Weiheng, Ding Li, ZHANG Junping. The expression of protein kinase CK2α in rat hepatic fibrogenesis process[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 518-521,575. doi: 10.3969/j.issn.1006-0111.2015.06.010
Citation: WANG Keqi, Xu Weiheng, Ding Li, ZHANG Junping. The expression of protein kinase CK2α in rat hepatic fibrogenesis process[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 518-521,575. doi: 10.3969/j.issn.1006-0111.2015.06.010
shu

蛋白激酶CK2α在大鼠肝纤维化病理过程中的表达变化

doi: 10.3969/j.issn.1006-0111.2015.06.010

  • 第二军医大学药学院生化药学教研室, 上海 200433

基金项目: 国家自然科学基金项目(No.81170404)

The expression of protein kinase CK2α in rat hepatic fibrogenesis process

  • Department of Biochemic Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 摘要: 目的 观察蛋白激酶casein kinaseⅡα(CK2α)在大鼠肝纤维化病理过程中的表达变化,以及10-甲氨基-8-硫代苦参碱(MASM)抗肝纤维化治疗对CK2α表达的影响。 方法 采用二甲基亚硝胺(DMN)和胆管结扎术(BDL)的方法建立大鼠肝纤维化模型,造模后灌胃给予MASM(50 mg/kg)和生理盐水进行治疗。肝组织切片分别采用苏木精-伊红染色进行病理分析,用天狼星红和Masson胶原染色判定肝纤维化程度,免疫组织化学法观察纤维化肝组织中CK2α和α-平滑肌肌动蛋白(α-SMA)的表达变化。 结果 与对照组相比,DMN及BDL诱导的肝纤维化组织中CK2α的表达水平均显著上调;注射DMN造模1~4周,随着造模时间的延长,α-SMA表达逐渐增加,CK2α的表达水平相应显著上调;与模型组相比,MASM药物治疗组大鼠肝纤维化程度明显缓解,同时CK2α 的表达水平显著下调。 结论 蛋白激酶CK2α的表达水平与肝纤维化的形成呈正相关关系;苦参碱衍生物MASM抗肝纤维化作用伴随下调CK2α的表达水平,提示CK2α是一个肝纤维化治疗的潜在靶点。
    Abstract: Objective To observe the dynamic characteristics of protein kinase, casein kinase II α (CK2α), expression during hepatic fibrogenesis in rats;and the effects of a matrine derivative, 13-methylamino-18-thione-matrine (MASM), on CK2α expression when it is used for anti-fibrotic treatment. Methods Hepatic fibrosis model was established in SD rats by dimethylnitrosamine (DMN) injection or by bile duct ligation (BDL). The established fibrotic rats were given 50 mg/kg MASM or saline as a control by gavage for three weeks. The level of hepatic fibrosis was evaluated by histopathology examination using hematoxylin-eosin staining, and using the sirius red and Masson's trichrome staining for collagen determination in fibrosis. The expressions of CK2α and α-smooth muscle actin (α-SMA) in hepatic tissues were detected by immunohistochemisry. Results CK2α is mainly expressed in the stellate cells of fibrotic livers induced by DMN or BDL comparing the control group. Along with the development of hepatic fibrosis as evidenced by α-SMA expression, increased CK2α-positive cells in liver were detected while injecting DMN in the rats for one to four weeks. MASM treatment significantly inhibited the hepatic fibrosis and suppressed the expression of CK2α comparing the model group. Conclusion The expression level of CK2α, and hepatic fibrosis formation are positively correlated. The matrine derivative, MASM, can significantly inhibit hepatic fibrosis and suppress the CK2α expression. These Results suggest CK2α may be a potential target for hepatic fibrosis therapy.
  • [1] Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis[J]. Best Pract Res Clin Gastroenterol, 2011, 25(2):195-206.
    [2] Friedman SL. Mechanisms of hepatic fibrogenesis[J]. Gastroenterology, 2008, 134(6):1655-1669.
    [3] Rippe RA, Brenner DA. From quiescence to activation:gene regulation in hepatic stellate cells[J]. Gastroenterology, 2004, 127(4):1260-1262.
    [4] Cozza G, Bortolato A, Moro S. How druggable is protein kinase CK2 ?[J]. Med Res Rev, 2010, 30(3):419-62.
    [5] Wang D, Westerheide SD, Hanson JL, et al. Tumor necrosis factor alpha-induced phosphorylation of ReIA/p65 0n Ser529 is controlled by casein kinase Ⅱ[J]. J Biol Chem, 2000, 275(42):32592-32597.
    [6] Rodriguez FA. Contreras C, Bolanos-Garcia V, et al. Protein kinase CK2 as an ectokinase: the role of the regulatory CK2 beta subunit[J]. Proc Natl Acad Sci(USA), 2008, 105(15):5693-5698.
    [7] Prudent R, Cochet C. New protein kinase CK2 inhibitors: jumping out of the catalytic box[J]. Chem Biol, 2009, 16(2):112-120.
    [8] Shi D,Zhang J,Qiu L,et al.Matrine inhibits infiltration of the inflammatory gr1(hi) monocyte subset in injured mouse liver through inhibition of monocyte chemoattractant protein-1[J].Evid Based Compl Alternat Med,2013,2013:580673.
    [9] Wang W, You RL, Qin WJ, et al. Anti-tumor activities of active ingredients in compound Kushen injection[J]. Acta Pharmacol Sin, 2015, 36(6):676-679.
    [10] Yang Y, Xiu J, Zhang X, et al. Antiviral effect of matrine against human enterovirus 71[J]. Molecules, 2012, 17(9):10370-10376.
    [11] Zhang JP, Zhang M, Zhou JP, et al. Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats[J]. Acta Pharmacol Sin, 2001, 22(2):183-186.
    [12] Hu H,Wang S,Zhang C,et al.Synthesis and in vitro inhibitory activity of matrine derivatives towards pro-inflammatory cytokines[J].Bioorg Med Chem Lett,2010,20(24):7537-7539.
    [13] Xu WH, Hu HG, Tian Y, et al. Bioactive compound reveals a novel function for ribosomal protein S5 in hepatic stellate cell activation and hepatic fibrosis[J]. Hepatology, 2014, 60(2): 648-660.
    [14] Xu Y, Peng Z, Ji W, et al. A novel matrine derivative WM130 inhibits activation of hepatic stellate cells and attenuates dimethylnitrosamine-induced liver fibrosis in rats[J]. Biomed Res Int, 2015, 2015:203978.
    [15] Qian L, Liu Y, Xu Y, et al. Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways[J]. Cancer Lett, 2015, 368(1):126-134.
  • [1] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 1-6. doi: 10.12206/j.issn.2097-2024.202312054
    [2] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [3] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [4] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2749
  • HTML全文浏览量:  214
  • PDF下载量:  242
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-06-10
  • 修回日期:  2015-10-11

蛋白激酶CK2α在大鼠肝纤维化病理过程中的表达变化

doi: 10.3969/j.issn.1006-0111.2015.06.010
  • 第二军医大学药学院生化药学教研室, 上海 200433
    • 基金项目:  国家自然科学基金项目(No.81170404)
  • 收稿日期: 2015-06-10
  • 修回日期: 2015-10-11

摘要: 目的 观察蛋白激酶casein kinaseⅡα(CK2α)在大鼠肝纤维化病理过程中的表达变化,以及10-甲氨基-8-硫代苦参碱(MASM)抗肝纤维化治疗对CK2α表达的影响。 方法 采用二甲基亚硝胺(DMN)和胆管结扎术(BDL)的方法建立大鼠肝纤维化模型,造模后灌胃给予MASM(50 mg/kg)和生理盐水进行治疗。肝组织切片分别采用苏木精-伊红染色进行病理分析,用天狼星红和Masson胶原染色判定肝纤维化程度,免疫组织化学法观察纤维化肝组织中CK2α和α-平滑肌肌动蛋白(α-SMA)的表达变化。 结果 与对照组相比,DMN及BDL诱导的肝纤维化组织中CK2α的表达水平均显著上调;注射DMN造模1~4周,随着造模时间的延长,α-SMA表达逐渐增加,CK2α的表达水平相应显著上调;与模型组相比,MASM药物治疗组大鼠肝纤维化程度明显缓解,同时CK2α 的表达水平显著下调。 结论 蛋白激酶CK2α的表达水平与肝纤维化的形成呈正相关关系;苦参碱衍生物MASM抗肝纤维化作用伴随下调CK2α的表达水平,提示CK2α是一个肝纤维化治疗的潜在靶点。

English Abstract

王珂琪, 许维恒, 丁力, 张俊平. 蛋白激酶CK2α在大鼠肝纤维化病理过程中的表达变化[J]. 药学实践与服务, 2015, 33(6): 518-521,575. doi: 10.3969/j.issn.1006-0111.2015.06.010
引用本文: 王珂琪, 许维恒, 丁力, 张俊平. 蛋白激酶CK2α在大鼠肝纤维化病理过程中的表达变化[J]. 药学实践与服务, 2015, 33(6): 518-521,575. doi: 10.3969/j.issn.1006-0111.2015.06.010
shu
WANG Keqi, Xu Weiheng, Ding Li, ZHANG Junping. The expression of protein kinase CK2α in rat hepatic fibrogenesis process[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 518-521,575. doi: 10.3969/j.issn.1006-0111.2015.06.010
Citation: WANG Keqi, Xu Weiheng, Ding Li, ZHANG Junping. The expression of protein kinase CK2α in rat hepatic fibrogenesis process[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 518-521,575. doi: 10.3969/j.issn.1006-0111.2015.06.010
shu

    全文HTML

参考文献 (15)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计